PANOVA-3: A phase III study of TTFields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC)

被引：0
|
作者：
Weinberg, Uri [1 ]
Farber, Ori [2 ]
Giladi, Moshe [2 ]
Bomzon, Zeev [2 ]
Lavy-Shahaf, Gitit [2 ]
Kirson, Eilon D. [2 ]
机构：
[1] Novocure GmbH, Root, Switzerland
[2] Novocure, Haifa, Israel
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT157
引用
收藏
页数：2
相关论文
共 50 条
  • [31] TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC)
    Guo, Xi
    Zhou, Yuhong
    Ji, Yuan
    Lou, Wenhui
    Wu, Lili
    Wang, Wenquan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] A retrospective study of gemcitabine with nab-paclitaxel as third-line retreatment in advanced pancreatic adenocarcinoma
    McSweeney, T.
    Das, A.
    O'Mahony, A.
    O'Tighearnaigh, F.
    O'Byrne, L.
    Feely, M.
    Passmore, E.
    Keane, S.
    Lanigan, S.
    Fitzgerald, S.
    Browne, T.
    De Beer, V.
    Dean, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S126 - S126
  • [33] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [34] The Phase 1 Study of Concurrent Chemoradiation Therapy With Gemcitabine and Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma Patients
    Ioka, T.
    Katayama, K.
    Takada, R.
    Fukutake, N.
    Ohkawa, K.
    Akita, H.
    Takahashi, H.
    Konishi, K.
    Teshima, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S205 - S205
  • [35] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [36] Use of phenotypic profiling to determine sensitivity of gemcitabine with nab-paclitaxel for front-line treatment of pancreatic cancer.
    Ricigliano, Mark
    Cooper, Brandon
    Bartlett, Andrew
    Yu, Kenneth H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga Olanrele
    Bedoya, Ivan Dario
    Mierzwa, Michelle Lynn
    Torregroza, Maria Patricia
    Dwivedi, Alok Kumar
    Wang, Jiang
    Smith, Milton T.
    Schmulewitz, Nathan
    Kucera, Stephen
    Choe, Kyuran Ann
    Ristagno, Ross
    Rudich, Steven
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Mozzillo, Eleonora
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    CANCERS, 2021, 13 (19)
  • [39] Phase I study of chemoradiation therapy (nab-paclitaxel/Gemcitabine) in 15 patients with unresectable locally advanced pancreatic cancer (UR-LAPC).
    Sueyoshi, Hironari
    Ioka, Tatsuya
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [40] Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first line gemcitabine for advanced pancreatic adenocarcinoma
    McNulty, M.
    Dean, A.
    Das, A.
    Gordon, M.
    ANNALS OF ONCOLOGY, 2018, 29
12345